CytoAgents is developing CTO1681, an orally bioavailable immunomodulator that targets the NF-kB signaling pathway to downregulate over 25 cytokines involved in Cytokine Release Syndrome (CRS). This therapy aims to mitigate the life-threatening immune overreaction commonly seen in patients undergoing CAR T-cell therapy, improving patient outcomes and reducing the need for hospitalization.
Funding
$38.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NIFounders
Product
Problem
Cytokine Release Syndrome (CRS), a potentially life-threatening immune overreaction, is a common and severe complication in patients undergoing CAR T-cell therapy and other immunotherapies. Current treatments often require hospitalization, ICU resources, and powerful steroid treatments, leading to significant morbidity and healthcare costs.
Solution
CytoAgents is developing CTO1681, an orally bioavailable immunomodulator designed to treat CRS by targeting the NF-kB signaling pathway. CTO1681 safely downregulates the production of over 25 cytokines involved in CRS, effectively stopping the cytokine storm and rebalancing the body’s immune response. This approach aims to improve patient outcomes, reduce the need for intensive care, and expand patient access to CAR T-cell therapy and other immunotherapies. CTO1681's mechanism of action modulates cytokine amplification while keeping the immune system functionally intact. The treatment is currently in a Phase 1b/2a clinical trial for CRS in patients receiving CAR T-cell therapy.
Target Audience
The primary target audience includes patients undergoing CAR T-cell therapy and other immunotherapies who are at risk of developing Cytokine Release Syndrome, as well as oncologists and hematologists treating these patients.
Features
- Orally bioavailable formulation for convenient administration
- Highly specific mechanism of action targeting the NF-kB signaling pathway
- Downregulation of over 25 CRS-inducing cytokines
- Demonstrated efficacy in preclinical models
- Phase 1 clinical trial complete with proven safety profile
- Phase 1b/2a clinical trial initiated for CAR T-cell therapy-related CRS